Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 117 results for embolism

  1. Minimally invasive total hip replacement (HTG236)

    Evidence-based recommendations on minimally invasive total hip replacement. This involves replacing the damaged hip joint (the top part of the upper leg bone and the socket in the hip bone that it fits into) with an artificial one.

    HealthTech guidance
    Published
    27 October 2010
    View recommendations

    Sections for HTG236

  2. Ultrasound-guided foam sclerotherapy for varicose veins (HTG301)

    Evidence-based recommendations on ultrasound guided foam sclerotherapy for varicose veins. This involves mixing a chemical with air or another gas to produce a foam, which is injected into the affected vein using ultrasound imaging to monitor its progress.

    HealthTech guidance
    Published
    23 February 2013
    View recommendations

    Sections for HTG301

  3. Endovascular stent insertion for intracranial atherosclerotic disease (HTG288)

    Evidence-based recommendations on endovascular stent insertion for intracranial atherosclerotic disease. This involves inflating a balloon catheter inserted into an artery in the arm or leg, and positioning a stent in the narrowing to maintain improved blood flow.

    HealthTech guidance
    Published
    23 July 2012
    View recommendations

    Sections for HTG288

  4. Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

    Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Published
    23 September 2009
    View recommendations

    Sections for TA179

  5. Research into the long-term treatment effects of rivaroxaban is needed.

    details Comes from guidance Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism Number TA287

    Research recommendation
    Published
    9 June 2015

  6. Further research on the clinical effectiveness of rivaroxaban compared with low molecular weight heparin (LMWH) in patients with active cancer should be conducted.

    thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Number TA261 Date issued July 2012 Other details

    Research recommendation
    Published
    9 June 2015

  7. There is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.

    Comes from guidance Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation Number TA275

    Research recommendation
    Published
    9 June 2015

  8. During this appraisal it was noted that there is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.

    Comes from guidance Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation Number TA275

    Research recommendation
    Published
    10 August 2021

  9. Further research should be in the form of randomised controlled trials or registries. It should report:

    Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism Number IPG778 Date issued November 2023 Other

    Research recommendation
    Published
    11 January 2024

  10. Duration of prophylaxis for elective total hip replacement surgery:- What is the clinical and cost effectiveness of standard versus extended duration pharmacological prophylaxis for preventing VTE in people undergoing elective total hip replacement surgery?

    reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other details

    Research recommendation
    Published
    15 November 2018

  11. Effects of HRT on venous thromboembolism risk:- How does the preparation of HRT affect the risk of venous thromboembolism (VTE)?

    An increase in the risk of VTE (deep vein thrombosis [DVT] or pulmonary embolism [PE]) is a significant side effect of HRT, particularly...

    Research recommendation
    Published
    11 December 2015

  12. Aspirin prophylaxis for people with fragility fractures of the pelvis, hip or proximal femur:- What is the clinical and cost effectiveness of aspirin alone versus other pharmacological and/or mechanical prophylaxis strategies (alone or in combination) for people with fragility fractures of the pelvis, hip or proximal femur?

    reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other details

    Research recommendation
    Published
    15 November 2018

  13. Apixaban for preventing venous thromboembolism after hip or knee replacement surgery (TA245)

    Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after hip or knee replacement in adults.

    Technology appraisal guidance
    Published
    25 January 2012
    View recommendations

    Sections for TA245

  14. Direct oral anticoagulants for people with lower limb immobilisation:- What is the clinical and cost effectiveness of direct oral anticoagulants for preventing VTE in people with lower limb immobilisation?

    reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other details

    Research recommendation
    Published
    15 November 2018

  15. Dose strategies for people who are obese:- What is the clinical and cost effectiveness of weight-based dose-adjustment strategies of lowmolecular-weight heparin (LMWH) compared with fixed-dose strategies of LMWH for preventing VTE in people who are very obese (BMI over 35) who are admitted to hospital or having day procedures (including surgery and chemotherapy)?

    reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other details

    Research recommendation
    Published
    15 November 2018